Bcl-10 (B-Cell lymphoma/Leukemia 10,B-Cell CLL/lymphoma 10,Bcl-10,CARD-Containing Molecule enhancing NF-kappa-B,CARD-like Apoptotic Protein,hCLAP,CED-3/ICH-1 prodomain Homologous E10-like Regulator,CIPER,Cellular Ho

Antibodies / Antibodies-Apoptosis

-20°C

Supplied as a liquid PBS,  0.1% sodium azide,  50% glycerol.

Recombinant full length Human Bcl-10.

Bcl10, also designated CIPER, c-CARMEN and mE10, was first identified as a gene truncated or mutated in MALT B cell lymphomas and other tumor types. Bcl10 is homologous to the equine herpesvirus-2 E10 gene and, like E10, it contains an N-terminal caspase recruitment domain (CARD). Expression of Bcl10 has been shown to induce NF˚B activation in a NIK-dependent pathway, and research indicates that the CARD domain is essential for this activation; although in a separate study, Bcl10 by itself did not induce JNK or NF˚B activation. Overexpression of Bcl10 has been shown to induce apoptosis in a manner dependent on CARD-mediated oligomerization. Bcl10 has also been shown to play a role in processing of caspase-9 to its active dimer. Other studies have shown that Bcl10 is not mutated in many human tumors and lymphomas.


Applications:
Suitable for use in Western Blot, Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Western Blot: 1:500-1:2000
Immunohistochemistry: 1:50-1:200
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.